Physician profile
Susan Boyd
NPI 1164431516
$3,084.24
in general payments reported to CMS, 2019-2025
21 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $249 · 2021: $777 · 2022: $101 · 2023: $411 · 2024: $656 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,317 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,316.74 |
| Education | $182.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $738.49 | 2019-2025 | Austedo Xr, Uzedy |
| Alkermes, INC. | $351.31 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $298.11 | 2020-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $264.42 | 2019-2024 | Abilify Maintena, Abilify Asimtufii |
| Allergan, INC. | $224.25 | 2019 | |
| Neurocrine Biosciences, INC. | $223.54 | 2019-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $199.71 | 2019-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $150.05 | 2024-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $140.78 | 2020-2025 | Fanapt |
| Axsome Therapeutics, INC. | $123.75 | 2024 | Auvelity |
| Eisai INC. | $109.01 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $45.19 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $41.69 | 2021-2022 | |
| Indivior INC. | $41.42 | 2022 | |
| Lundbeck LLC | $24.10 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22.20 | 2025 | |
| Owp Pharmaceuticals, INC. | $20.94 | 2021 | |
| Corium, LLC | $18.93 | 2022 | |
| Vertical Pharmaceuticals, LLC | $17.22 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.20 | 2025 | Cobenfy |
| Novo Nordisk INC | $13.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.